drugset
drugset / Trial / NCT02599194

18F-FSPG PET/CT for Cancer Patients on Therapy

NCT02599194 ↗

Phase 2 Completed 7 enrolled Andrei Iagaru National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelDiagnostic

Summary

The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic cancers.

Timeline

Start
2015-07
Primary completion
2016-12-14
Completion
2016-12-14

Publications

  • Results Park P, Hatami N, Rutledge O, Koglin N, Loo B, Fan A, Mittra E. J Nucl Med. 58(suppl 1, no 118), 1 May 2017.

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FDG Diagnostic / imaging agent — Intravenous
Subject 18F-FSPG Diagnostic / imaging agent — Intravenous

Indications

B-cell neoplasm malignant mesothelioma non-small cell lung carcinoma renal cell carcinoma triple-negative breast carcinoma